- Home
- INM vs TSI Comparison
INM vs TSI Comparison
Compare INM & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- TSI
- Stock Information
- Founded
- INM 1981
- TSI 1987
- Country
- INM Canada
- TSI United States
- Employees
- INM N/A
- TSI N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- INM Health Care
- TSI Finance
- Exchange
- INM Nasdaq
- TSI Nasdaq
- Market Cap
- INM 5.0M
- TSI 235.1M
- IPO Year
- INM N/A
- TSI N/A
- Fundamental
- Price
- INM $1.71
- TSI $4.92
- Analyst Decision
- INM
- TSI
- Analyst Count
- INM 0
- TSI 0
- Target Price
- INM N/A
- TSI N/A
- AVG Volume (30 Days)
- INM 84.4K
- TSI 106.8K
- Earning Date
- INM 11-13-2025
- TSI 01-01-0001
- Dividend Yield
- INM N/A
- TSI 7.46%
- EPS Growth
- INM N/A
- TSI N/A
- EPS
- INM N/A
- TSI N/A
- Revenue
- INM $4,942,633.00
- TSI N/A
- Revenue This Year
- INM N/A
- TSI N/A
- Revenue Next Year
- INM N/A
- TSI N/A
- P/E Ratio
- INM N/A
- TSI N/A
- Revenue Growth
- INM 7.50
- TSI N/A
- 52 Week Low
- INM $1.67
- TSI $4.48
- 52 Week High
- INM $8.27
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- INM 27.29
- TSI 47.17
- Support Level
- INM $1.67
- TSI $4.83
- Resistance Level
- INM $1.92
- TSI $4.96
- Average True Range (ATR)
- INM 0.09
- TSI 0.04
- MACD
- INM -0.03
- TSI 0.00
- Stochastic Oscillator
- INM 7.75
- TSI 69.23
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.